Collegium Pharmaceutical (COLL) Gross Profit (2016 - 2026)

Collegium Pharmaceutical's Gross Profit history runs 11 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 20.47% year-over-year to $117.2 million in Q1 2026; TTM through Mar 2026 was $483.2 million, a 26.09% increase from a year earlier, with the FY2025 full-year figure at $463.3 million, up 22.77% from the prior year.
• Gross Profit fell to $117.2 million in Q1 2026 per COLL's latest filing, from $128.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $129.2 million in Q3 2025 and bottomed at $48.5 million in Q1 2022.
• The 5-year median for Gross Profit is $91.5 million (2024), against an average of $87.9 million.
• Biggest YoY gain for Gross Profit was 3835.11% in 2022; the steepest drop was 12.77% in 2022.
• Year by year, Gross Profit stood at $49.8 million in 2022, then jumped by 90.06% to $94.6 million in 2023, then climbed by 3.87% to $98.3 million in 2024, then surged by 30.61% to $128.4 million in 2025, then retreated by 8.67% to $117.2 million in 2026.
• Per Business Quant, the three latest COLL Gross Profit figures stand at $117.2 million (Q1 2026), $128.4 million (Q4 2025), and $129.2 million (Q3 2025).